Leneva I A, Falynskova I N, Leonova E I, Fedyakina I T, Makhmudova N R, Osipova E A, Lepekha L N, Mikhailova N A, Zverev V V
Antibiot Khimioter. 2014;59(9-10):17-24.
Pneumonia often occurs as a secondary infection after influenza and accounts for a large proportion of the morbidity and mortality associated with seasonal and pandemic influenza outbreaks. The efficacy of umifenovir (Arbidol) was investigated on a murine model of S. aureus pneumonia following A/California/04/2009 (H1N1) influenza virusinfection. Oral treatment with umifenovir (40 and 60 mg/kg/day) in all the contamination schemes increased the survival rate in the mice from 0% to 90% and lowered the animal weight loss. The umifenovir treatment also decreased the virus titer by ≥ 2 logs and the viable bacteria counts in the lungs of the mice. The lungs of the mice treated with umifenovir had less severe histopathologic lesions compared to the control group.
肺炎常作为流感后的继发感染出现，在季节性和大流行性流感暴发相关的发病和死亡中占很大比例。在A/加利福尼亚/04/2009（H1N1）流感病毒感染后的金黄色葡萄球菌肺炎小鼠模型上研究了乌米芬诺尔（阿比多尔）的疗效。在所有感染方案中，用乌米芬诺尔（40和60毫克/千克/天）进行口服治疗可使小鼠存活率从0%提高到90%，并减轻动物体重减轻。乌米芬诺尔治疗还使病毒滴度降低≥2个对数，并减少了小鼠肺部的活菌计数。与对照组相比，用乌米芬诺尔治疗的小鼠肺部组织病理学损伤较轻。
